Therapeutic monitoring of 120 hours continuous 5-fluorouracil associated with cisplatin.

被引:0
|
作者
Coudert, B [1 ]
DeGislain, C [1 ]
Beltramo, JL [1 ]
Guigues, B [1 ]
Mayer, F [1 ]
Bruchon, Y [1 ]
Riedinger, JM [1 ]
Fargeot, P [1 ]
Dumas, M [1 ]
Guerrin, J [1 ]
机构
[1] CHU, TOXICOL LAB, F-21034 DIJON, FRANCE
关键词
5-fluorouracil; therapeutic monitoring;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For 31 patients treated by continuous 5-fluorouracil with cisplatin, a therapeutic monitoring of 5-fluorouracil is performed, based on the 48 first hours area under the curve (AUC) and the total AUC. The 5-fluorouracile taylorization allows to reduce some toxicity's while preserving art efficiency (objective responses 42%). Many patients are considered with potentially low 5-fluorouracile clearance. Dose reductions of 5-fluorouracile are frequent, reach 50% during the third cure and allow the achievement of targeted AUC. The role of cisplatin in this necessary reduction of dose is unknown.
引用
收藏
页码:847 / 852
页数:6
相关论文
共 50 条
  • [1] Palliative treatment in advanced pancreatic cancer with 5-fluorouracil/cisplatin.
    Charles, A
    Heider, A
    Zimmermann, J
    Siedek, M
    Niederle, N
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [2] Therapeutic drug monitoring of 5-fluorouracil
    Lee, James J.
    Beumer, Jan H.
    Chu, Edward
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 447 - 464
  • [3] Therapeutic drug monitoring of 5-fluorouracil
    James J. Lee
    Jan H. Beumer
    Edward Chu
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 78 : 447 - 464
  • [4] ASSOCIATION OF BOLUS TETRAHYDROPYRANYL ADRIAMYCIN AND 120 HOURS CONTINUOUS 5-FLUOROURACIL INFUSION IN PATIENTS WITH METASTATIC BREAST-CANCER
    CHEVALLIER, B
    FUMOLEAU, P
    KERBRAT, P
    MONNIER, A
    ROCHE, H
    GOUDIE, MJ
    HERAIT, P
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 : S40 - S43
  • [5] PHARMACOKINETICS OF 5-FLUOROURACIL ADMINISTERED IN CONTINUOUS PERFUSION - EFFECTS OF THE ASSOCIATION WITH CISPLATIN
    BASTIAN, G
    DEMARCQ, C
    LETEURTRE, F
    BERTHAU, N
    POUILLART, P
    PALANGIE, T
    DORVAL, T
    JOUVE, M
    GARCIAGIRALT, E
    [J]. BULLETIN DU CANCER, 1986, 73 (04) : 455 - 455
  • [6] THE ROLE OF DRUG SEQUENCE IN THERAPEUTIC SELECTIVITY OF THE COMBINATION OF 5-FLUOROURACIL AND CISPLATIN
    PALMERI, S
    TRAVE, F
    RUSSELLO, O
    RUSTUM, YM
    [J]. SELECTIVE CANCER THERAPEUTICS, 1989, 5 (04): : 169 - 177
  • [7] Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs
    Hashimoto, Yasuhiro
    Yoshida, Yoichiro
    Yamada, Teppei
    Aisu, Naoya
    Yoshimatsu, Gumpei
    Yoshimura, Fumihiro
    Hasegawa, Suguru
    [J]. ANTICANCER RESEARCH, 2020, 40 (08) : 4655 - 4661
  • [8] Docetaxol 5-Fluorouracil, Cisplatin versus Epirubicin, 5-Fluorouracil, Cisplatin for advanced gastric carcinoma: Preliminary report
    Sadighi, Sanambar
    Mohagheghi, M. A.
    Raafat, J.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 235 - 235
  • [9] TREATMENT OF ADVANCED ADENOCARCINOMA OF THE ESOPHAGUS AND STOMACH WITH EPIRUBICIN, CISPLATIN, AND CONTINUOUS 5-FLUOROURACIL
    MASON, RC
    HIGHLEY, M
    BRIGHT, N
    HILL, M
    BARKER, S
    CUNNINGHAM, D
    HARPER, P
    [J]. GUT, 1991, 32 (10) : A1211 - A1211
  • [10] CONTINUOUS-INFUSION CISPLATIN AND BOLUS 5-FLUOROURACIL IN COLORECTAL-CARCINOMA
    POSNER, MR
    BELLIVEAU, JF
    WEITBERG, AB
    SABBATH, K
    WIEMANN, MC
    CUMMINGS, FJ
    CALABRESI, P
    [J]. CANCER TREATMENT REPORTS, 1987, 71 (10): : 975 - 977